Transfusion-dependent β-thalassemia (TDT) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
β-thalassemia are monogenic disorders usually caused by reduced or absent synthesis of the βglobin chain, one of the main components of adult hemoglobin (HbA, α2β2. This results in a relative increase in the unattached αglobin chains (α/β-chain imbalance) that form insoluble Hemi-chromes in the erythrocyte progenitors. The Hemi-chromes damage the erythrocyte membrane, leading to severe intramedullary erythrocyte apoptosis (ineffective erythropoiesis, IE) and severely shortened red blood cell (RBC) life span due to extra-medullary hemolysis, leading to severe anemia.
·
Transfusion-dependent
β-thalassemia (TDT) is the most severe form of the disease, characterized by
severe anemia, and requires lifelong, regular blood transfusions to maintain Hb
levels. These transfusions carry the risk of progressive multi-organ damage due
to unavoidable iron overload
· In the USA the estimated β-thalassemia cases range
between 1.5 to 2.6 cases per 100,000 population, however it varies based on
geographic presence
The competitive
landscape of Transfusion-dependent β-thalassemia (TDT) includes country-specific
approved as well as pipeline therapies. Any asset/product-specific designation
or review and Accelerated Approval are being tracked and supplemented with
analyst commentary.
KOLs insights of Transfusion-dependent
β-thalassemia (TDT) across 8 MM market from the center of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Transfusion-dependent
β-thalassemia (TDT) Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 ST-400 Sangamo
Therapeutics Phase 2
2 CTX001 CRISPR
Therapeutics Phase 2
3 ET-01 EdiGene
(GuangZhou) Inc. Phase 1
4 VIT-2763 Vifor
Pharma Phase 2
5 OTL-300 Orchard
Therapeutics Phase 2
6 LentiGlobin BB305 bluebird
bio Phase 3
7 Mitapivat Agios
Pharmaceuticals, Inc. Phase 3
8 PTG-300 Protagonist
Therapeutics, Inc. Phase 2
9 Deferasirox Novartis
Pharmaceuticals Phase 2
Comments
Post a Comment